Cargando…

Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia

Cytokine release syndrome (CRS), which may be associated with fever, hypotension, hypoxia, and organ damage, is caused by a massive cytokine release after chimeric antigen receptor (CAR)-T cell therapy. We present the case of a patient who developed severe bloody diarrhea due to CRS after CAR-T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Shima, Haruko, Ishikawa, Takahiro, Ito, Jumpei, Emoto, Katsura, Kurosawa, Takumi, Keino, Dai, Yamazaki, Fumito, Goto, Hiroaki, Shimada, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia-Pacific Blood and Marrow Transplantation Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847265/
https://www.ncbi.nlm.nih.gov/pubmed/36714263
http://dx.doi.org/10.31547/bct-2021-009
_version_ 1784871419375517696
author Shima, Haruko
Ishikawa, Takahiro
Ito, Jumpei
Emoto, Katsura
Kurosawa, Takumi
Keino, Dai
Yamazaki, Fumito
Goto, Hiroaki
Shimada, Hiroyuki
author_facet Shima, Haruko
Ishikawa, Takahiro
Ito, Jumpei
Emoto, Katsura
Kurosawa, Takumi
Keino, Dai
Yamazaki, Fumito
Goto, Hiroaki
Shimada, Hiroyuki
author_sort Shima, Haruko
collection PubMed
description Cytokine release syndrome (CRS), which may be associated with fever, hypotension, hypoxia, and organ damage, is caused by a massive cytokine release after chimeric antigen receptor (CAR)-T cell therapy. We present the case of a patient who developed severe bloody diarrhea due to CRS after CAR-T cell infusion. A 10-year-old boy presented with a second relapse of B-cell precursor acute lymphoblastic leukemia 6 months after hematopoietic stem cell transplantation from an unrelated donor. CAR-T cells (tisagenlecleucel) were infused at the third complete remission after salvage chemotherapy. While fever >39°C was sustained from day 4, circulatory and respiratory status remained stable. However, he experienced severe bloody diarrhea. There was no evidence of infection; lower gastrointestinal (GI) endoscopy revealed extensive edema with erosion and ulceration, suggestive of non-specific intestinal inflammation. Thus, we considered CRS-associated grade 3 GI damage and administered a single dose of tocilizumab for grade 2 CRS, followed by 4 days of corticosteroids. Afterwards, no fever or GI bleeding was observed. Biopsy of the intestinal mucosa revealed ulcerative change with a lack of epithelial cells, which may correspond to histologic grade 4 graft versus host disease (GVHD). However, diarrhea corresponded to stage 1 GVHD, and the GVHD risk after CAR-T cell infusion has been reported to be rare in clinical practice. Although severe GI symptoms associated with CRS after CAR-T therapy are rare, early tocilizumab use is recommended for non-infectious severe GI symptoms to avoid long-term corticosteroid use, which may reduce CAR-T cell efficacy.
format Online
Article
Text
id pubmed-9847265
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Asia-Pacific Blood and Marrow Transplantation Group
record_format MEDLINE/PubMed
spelling pubmed-98472652023-01-27 Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia Shima, Haruko Ishikawa, Takahiro Ito, Jumpei Emoto, Katsura Kurosawa, Takumi Keino, Dai Yamazaki, Fumito Goto, Hiroaki Shimada, Hiroyuki Blood Cell Ther Case Report Cytokine release syndrome (CRS), which may be associated with fever, hypotension, hypoxia, and organ damage, is caused by a massive cytokine release after chimeric antigen receptor (CAR)-T cell therapy. We present the case of a patient who developed severe bloody diarrhea due to CRS after CAR-T cell infusion. A 10-year-old boy presented with a second relapse of B-cell precursor acute lymphoblastic leukemia 6 months after hematopoietic stem cell transplantation from an unrelated donor. CAR-T cells (tisagenlecleucel) were infused at the third complete remission after salvage chemotherapy. While fever >39°C was sustained from day 4, circulatory and respiratory status remained stable. However, he experienced severe bloody diarrhea. There was no evidence of infection; lower gastrointestinal (GI) endoscopy revealed extensive edema with erosion and ulceration, suggestive of non-specific intestinal inflammation. Thus, we considered CRS-associated grade 3 GI damage and administered a single dose of tocilizumab for grade 2 CRS, followed by 4 days of corticosteroids. Afterwards, no fever or GI bleeding was observed. Biopsy of the intestinal mucosa revealed ulcerative change with a lack of epithelial cells, which may correspond to histologic grade 4 graft versus host disease (GVHD). However, diarrhea corresponded to stage 1 GVHD, and the GVHD risk after CAR-T cell infusion has been reported to be rare in clinical practice. Although severe GI symptoms associated with CRS after CAR-T therapy are rare, early tocilizumab use is recommended for non-infectious severe GI symptoms to avoid long-term corticosteroid use, which may reduce CAR-T cell efficacy. Asia-Pacific Blood and Marrow Transplantation Group 2021-01-28 /pmc/articles/PMC9847265/ /pubmed/36714263 http://dx.doi.org/10.31547/bct-2021-009 Text en Copyright Ⓒ2022 Asia-Pacific Blood and Marrow Transplantation Group (APBMT). https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Case Report
Shima, Haruko
Ishikawa, Takahiro
Ito, Jumpei
Emoto, Katsura
Kurosawa, Takumi
Keino, Dai
Yamazaki, Fumito
Goto, Hiroaki
Shimada, Hiroyuki
Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
title Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
title_full Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
title_fullStr Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
title_full_unstemmed Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
title_short Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
title_sort severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor t cell therapy for refractory acute lymphoblastic leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847265/
https://www.ncbi.nlm.nih.gov/pubmed/36714263
http://dx.doi.org/10.31547/bct-2021-009
work_keys_str_mv AT shimaharuko severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT ishikawatakahiro severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT itojumpei severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT emotokatsura severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT kurosawatakumi severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT keinodai severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT yamazakifumito severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT gotohiroaki severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia
AT shimadahiroyuki severebloodydiarrheaduetocytokinereleasesyndromeafterchimericantigenreceptortcelltherapyforrefractoryacutelymphoblasticleukemia